Meaningful Engagement of Women in HIV Treatment Research

Metrodora, Meaningful Engagement of Women in HIV Treatment Research


Globally, women are disproportionally affected by HIV, and constitute more than half of all people living with HIV. Young women and adolescent girls are especially vulnerable, accounting for 46% of new infections in Eastern Europe and Central Asia and 29% in Western and Central Europe[1].

Women have been historically under-represented in clinical trials and consequently, many treatment guidelines contain minimal advice on the care of women and lack of understanding on their response to medications. In fact, less than a quarter of people taking part in clinical trials for antiretroviral medications are women, which limits the generalisability of research findings.2

New conjoint efforts and research are required to guide evidence-based practice and to develop more focused responses on HIV prevention and treatment for women living with HIV.


[1] UN Women – Facts and Figures: HIV and AIDS



The aim of the Metrodora project is to foster women’s involvement in Research and Development in the HIV field (henceforth: HIV R&D) and their active participation in decision-making processes. The project foresees 3 levels of activities: assessing the involvement of women in Eastern and Western European regions; empowering advocates; and enhancing collaborative efforts between key stakeholders to improve the involvement of women in HIV R&D. By the end of the project, it is expected key stakeholders involved in women’s HIV treatment and prevention research are jointly and actively contributing to increase women’s representation in HIV R&D processes.

Project Coordinator: This project is coordinated by the EATG office in collaboration with the EATG4Women steering committee.




First phase:

Literature review of the women’s involvement in HIV R&D; identification of gaps, obstacles, unmet needs and best practices. Development of a position paper.


Second phase:


Third phase:

Multi-stakeholders’ meeting between the women advocates and representatives from pharmaceutical companies, relevant international organisations, researchers and policy makers.